5 Key Takeaways

• 1

  Nuclera and leadXpro have partnered to enhance drug discovery for complex membrane proteins using AI/ML and rapid screening technologies.

• 2

  Membrane proteins are valuable drug targets but are difficult to express and purify, hindering structural biology studies.

• 3

  The collaboration aims to create an AI-guided workflow that integrates construct design with experimental multiplex screening.

• 4

  Promising membrane protein constructs will undergo biophysical characterization and cryo-EM structure determination.

• 5

  The partnership seeks to embed AI/ML capabilities into Nuclera’s system to expedite the transition from sequence to structural insights.